Peer Reviewed Articles 2011
-
Ozdemir, V. […] Joly, Y. et al., “Towards an Ecology of Collective Innovation: Human Variome Project (HVP), Rare Disease Consortium for Autosomal Loci (RaDiCAL) and Data-Enabled Life Sciences Alliance (DELSA)” 9 (2011) Current Pharmacogenomics and Personalized Medicine, 243-251.
-
Lévesque, E., Joly, Y., Simard, J., “Return of research results: General principles and international perspectives” 39:4 (2011) Journal of Law Medicine and Ethics, 583-592.
-
Dove, E., Joly, Y., Knoppers, B.M., “Trade-Secret Model: Legal Limitations” 333:6049 (2011) Science, 1575.
-
Kamal, S.M. […] Joly, Y. et al., “Forward Look: Tenth Anniversary of the Human Genome Sequence and 21st Century Postgenomics Global Health — A Close Up on Africa and Women's Health” 9:3 (2011) Current Pharmacogenomics and Personalized Medicine, 148-155.
-
Zawati, M.H., Hendy, M., Joly, Y., “Incidental Findings in Data-Intensive Postgenomics Science and Legal Liability of Clinician-Researchers: Ready for Vaccinomics?” 15:9 (2011) OMICS: A Journal of Integrative Biology, 615-624.
-
Joly, Y. et al., “Diagnostic Testing for Vaccinomics: Is the Regulatory Approval Framework Adequate? A Comparison of Canada, the United States, and Europe” 15:9 (2011) OMICS: A Journal of Integrative Biology. 597-605.
-
Joly, Y., Zeps, N., Knoppers, B.M., “Genomic Databases Access Agreements: Legal Validity and Possible Sanctions” 130:3 (2011) Human Genetics, 441–449.
-
Joly, Y., “Personalized Medicine in Developing Countries: A Roadmap to Personalized Innovation” 9:3 (2011) Current Pharmacogenomics and Personalized Medicine, 156-158.
-
Pathmasiri, S., Deschênes, M., Joly, Y. […], “Intellectual Property Rights in Publicly Funded Biobanks: Much Ado About Nothing?” 29:4 (2011) Nature Biotechnology, 319-323.
-
Howard, H.C., Joly, Y., Avard, D., Laplante, N., Phillips, M., Tardif, J.C., “Informed Consent in the Context of Pharmacogenomic Research: Ethical Considerations” 11:3 (2011) The Pharmacogenomics Journal, 155-161.
-
Madadi, P., Joly, Y. et al., “The communication of pharmacogenetic research results: Participants weigh in on their informational needs in a pilot study” 18:1 (2011) Canadian Journal of Population Therapeutics, e152-e155.
-
Ozdemir, V., Joly, Y., Knoppers, B.M., “ACCE, Pharmacogenomics, and Stopping Clinical Trials: Time to Extend the CONSORT Statement?” 11:3 (2011) The American Journal of Bioethics, 11-13.
-
Joly, Y. et al., “Regulatory Approval for New Pharmacogenomics Tests: A Comparative Overview” 66:1 (2011) Food and Drug Law Journal, 1-24.